Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19000472 | BETACORONA VIRUS mRNA VACCINES | December 2024 | June 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18964018 | Alpha-herpesvirus Insensitive Monoclonal Cell Strain, and Preparation Method Therefor and Use Thereof | November 2024 | April 2025 | Allow | 4 | 1 | 1 | No | No |
| 18762296 | BETACORONAVIRUS mRNA VACCINES | July 2024 | October 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18762372 | BETACORONAVIRUS RNA VACCINES | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18637070 | COMPOSITIONS TARGETING APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN WITH CASPASE ACTIVATION AND RECRUITMENT DOMAIN (ASC) AND METHODS OF USE | April 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18528323 | BETACORONAVIRUS MRNA VACCINES | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18494893 | NUCLEIC ACID BASE VACCINE AGAINST EMERGING SARS-CoV-2 VARIANTS | October 2023 | August 2024 | Allow | 10 | 2 | 1 | No | No |
| 18483149 | REDUCED FOAMING VACCINE COMPOSITIONS | October 2023 | April 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18453777 | Targeted Neoepitope Vectors And Methods Therefor | August 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18452307 | ONCOLYTIC VIRUSES TARGETING STAT3 | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18227761 | PRE-IMMUNIZATION AND IMMUNOTHERAPY | July 2023 | January 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18344924 | ANTIBACTERIAL COMPOSITION AND USES THEREOF | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18344926 | SOD1 DUAL EXPRESSION VECTORS AND USES THEREOF | June 2023 | January 2025 | Allow | 19 | 2 | 0 | No | No |
| 18203818 | Adenoviral Vectors Comprising Partial Deletions of E3 | May 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18169127 | COMPOSITION AND METHOD FOR ACTIVATING LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV) | February 2023 | March 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18163855 | NOROVIRUS VACCINE | February 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18146589 | COMPOSITIONS TO DETECT ADENOVIRUS NUCLEIC ACIDS | December 2022 | May 2025 | Allow | 29 | 1 | 1 | No | No |
| 18085751 | RETROVIRAL TRANSDUCTION USING POLOXAMERS | December 2022 | April 2025 | Allow | 28 | 2 | 0 | No | No |
| 18059117 | GENETICALLY STABLE RECOMBINANT MODIFIED VACCINIA ANKARA (RMVA) VACCINES AND METHODS OF PREPARATION THEREOF | November 2022 | February 2025 | Allow | 27 | 2 | 1 | No | No |
| 17903286 | SUSTAINED RELEASE COWPEA MOSAIC VIRUS OR VIRUS-LIKE PARTICLE THERAPEUTIC CONSTRUCTS FOR THE TREATMENT OF CANCER | September 2022 | August 2024 | Allow | 24 | 2 | 0 | No | No |
| 17820256 | METHODS TO DETECT RHINOVIRUS NUCLEIC ACIDS | August 2022 | February 2025 | Allow | 30 | 1 | 2 | No | No |
| 17864757 | BACTERIAL DELIVERY VEHICLES COMPRISING TRACER NUCLEIC ACID SEQUENCES | July 2022 | March 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17855553 | NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE | June 2022 | September 2024 | Allow | 26 | 1 | 1 | No | No |
| 17844509 | ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | June 2022 | February 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17804954 | IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2 | June 2022 | July 2024 | Allow | 25 | 2 | 0 | No | No |
| 17750817 | COMPOSITIONS AND METHODS RELATED TO SURGE-ASSOCIATED SARS-COV-2 MUTANTS | May 2022 | August 2025 | Abandon | 39 | 3 | 1 | Yes | No |
| 17731027 | ENHANCED PROMOTER | April 2022 | December 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17713975 | METHODS OF TREATING BLADDER CANCER | April 2022 | March 2025 | Allow | 35 | 3 | 0 | No | No |
| 17705837 | Nucleoside-modified RNA for Inducing an Adaptive Immune Response | March 2022 | July 2024 | Allow | 27 | 1 | 1 | No | No |
| 17699573 | METHODS FOR IMPROVING NUCLEIC ACID CLUSTER CLONALITY | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17559190 | COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST ZIKA VIRUS | December 2021 | July 2024 | Allow | 31 | 2 | 1 | No | No |
| 17546967 | RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED HA FOR REPLICATION IN EGGS | December 2021 | October 2024 | Allow | 34 | 1 | 1 | No | No |
| 17453826 | IMMUNE COMPOSITION COMPRISING ANTIGEN AND GLYCOENGINEERED ANTIBODY THEREOF | November 2021 | September 2024 | Allow | 34 | 1 | 1 | No | No |
| 17466381 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | September 2021 | February 2025 | Allow | 41 | 1 | 1 | No | No |
| 17462842 | LOW-COST DETECTION OF NOROVIRUS USING PAPER-BASED CELL-FREE SYSTEMS AND SYNBODY-BASED VIRAL ENRICHMENT | August 2021 | May 2025 | Abandon | 44 | 4 | 1 | No | No |
| 17348636 | METHODS TO QUANTIFY VIRUS FROM WASTEWATER | June 2021 | July 2024 | Allow | 37 | 1 | 1 | No | No |
| 17335244 | RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USE | June 2021 | December 2024 | Allow | 42 | 2 | 1 | No | No |
| 17324856 | Methods and Systems for Quantitative Detection of Antibodies | May 2021 | April 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17319845 | PAPER-BASED COLORIMETRIC COVID-19/SARS-COV-2 TEST | May 2021 | April 2025 | Allow | 47 | 2 | 1 | No | No |
| 17317279 | SARS-CoV-2 Vaccines | May 2021 | October 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17290650 | EMULSION FORMULATION AND METHOD FOR PREPARING THE SAME | April 2021 | April 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17233479 | Virus detection | April 2021 | March 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17285453 | RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION | April 2021 | August 2024 | Allow | 40 | 2 | 1 | No | No |
| 17227350 | Methods and Compositions for Enhancing Vaccine Immune Responses | April 2021 | December 2024 | Abandon | 44 | 3 | 0 | No | No |
| 17163468 | VSV/NDV HYBRID VIRUSES FOR ONCOLYTIC THERAPY OF CANCER | January 2021 | December 2024 | Abandon | 47 | 3 | 1 | No | No |
| 17059507 | PHAGE COCKTAIL AGAINST E. COLI 0157 | November 2020 | May 2025 | Allow | 53 | 4 | 0 | No | No |
| 17058383 | AAV CAPSID POLYNUCLEOTIDES AND POLYPEPTIDES AND VIRIONS CONTAINING THE SAME | November 2020 | December 2024 | Allow | 49 | 0 | 1 | No | No |
| 17096681 | VIRAL CLEARANCE EVALUATION FOR BIOLOGICAL MEDICAL PRODUCT PREPARATION PROCESSES | November 2020 | September 2024 | Allow | 46 | 4 | 1 | Yes | No |
| 16979565 | METHOD FOR EXTRACTING NUCLEIC ACIDS | September 2020 | December 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16978219 | RECOMBINANT PSEUDOCOWPOXVIRUS | September 2020 | April 2025 | Allow | 55 | 4 | 1 | Yes | No |
| 16932337 | INTEGRATED SENSOR FOR THE RAPID IDENTIFICATION OF BACTERIA USING ISFETS | July 2020 | February 2025 | Abandon | 55 | 4 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner KINSEY WHITE, NICOLE ERIN works in Art Unit 1671 and has examined 21 patent applications in our dataset. With an allowance rate of 61.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner KINSEY WHITE, NICOLE ERIN's allowance rate of 61.9% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KINSEY WHITE, NICOLE ERIN receive 2.24 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KINSEY WHITE, NICOLE ERIN is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.4% benefit to allowance rate for applications examined by KINSEY WHITE, NICOLE ERIN. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.